Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib

The efficacy of osimertinib is severely limited by the emergence of EGFR C797S, which is detected in either the cis or trans position with T790M when osimertinib is used as a second-line treatment, and which is largely identified in combination with an EGFR 19 deletion. The EGFR T790M-cis-G796S muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yubo, Han, Rui, Zhu, Mengxiao, He, Tingting, He, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071300/
https://www.ncbi.nlm.nih.gov/pubmed/35530305
http://dx.doi.org/10.3389/fonc.2022.875313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071300/
https://www.ncbi.nlm.nih.gov/pubmed/35530305
http://dx.doi.org/10.3389/fonc.2022.875313

Ejemplares similares